Consensus $5.79. Lowers FY24 revenue view to $9.05B-$9.2B, consensus $9.16B. “As the leader in animal health, we understand our customers’ needs. Our innovation continues to be our differentiator, and we’ll continue to lead the way by investing in areas of unmet need to advance care for animals. The strength of the human-animal bond and the growing demand for a secure and sustainable food supply reinforce the essential nature of the animal health industry and our innovative portfolio. We will continue to deliver strong growth in 2024, while investing for the future.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis price target lowered to $180 from $195 at Stifel
- Zoetis price target lowered to $200 from $205 at BofA
- Zoetis to sell medicated feed additive portfolio to Phibro Animal Health
- Zoetis price target lowered to $230 from $260 at Barclays
- Jefferies cuts Zoetis target, says vet survey positive for Librela
Questions or Comments about the article? Write to editor@tipranks.com